Table 6.
Compound | B16F10 | SKMEL-28 | JMAR | MDA-1986 | MRC-5 |
---|---|---|---|---|---|
1 | >10 | 5.1 | 5.3 | 3.3 | >10 |
1a | 0.067 | 0.54 | 0.16 | 0.91 | 0.58 |
1b | 0.098 | 0.81 | 0.14 | 2.2 | 0.41 |
2 | 0.20 | 3.9 | 0.17 | 1.3 | 0.40 |
2a | 0.13 | 0.27 | 0.24 | 0.11 | 0.51 |
2b | 0.19 | 0.64 | 0.12 | 0.49 | 0.16 |
3 | 0.49 | 3.0 | 0.77 | 2.6 | 3.6 |
4 | 3.2 | 9.3 | 4.7 | >10 | 6.5 |
5 | 5.6 | >10 | >10 | 8.3 | 7.3 |
7 | 1.3 | 4.8 | 2.3 | 2.0 | 3.3 |
8 | >10 | >10 | 8.2 | 8.1 | 8.7 |
15 | 3.7 | 8.3 | 4.2 | >10 | 5.2 |
16 | 0.29 | 4.0 | 2.0 | 0.80 | 0.20 |
19 | 0.18 | 5.1 | 0.48 | 0.27 | 1.4 |
cisplatin (positive control) | 1.0 | 1.1 | 1.1 | 1.6 | 8.9 |
For cell lines used, see text. Withanolides 6, 9-14, 17, 18, 20 and 21 were inactive for all cell lines used (IC50 > 10 μM).